During 2021, the company faced rapid technological development, particularly with respect to computing, automation, artificial intelligence, mobile connectivity, communications, and digitization in most of its served markets. The company is making significant investments, both organically and through acquisitions, to address the rapid pace of technological change in its served markets and to globalize its manufacturing, research and development, and customer-facing resources. The company's ability to expand its business in high-growth geographies and segments, identify and integrate appropriate acquisitions, and develop innovative and differentiated new products and services is critical to its long-term growth and profitability. The company operates in a highly competitive business environment, and its long-term growth will depend on its ability to effectively address the demands of an increasingly regulated global environment. The company continues to monitor key competitors and customers to gauge relative performance and outlook for the future. The company has activated its business continuity plans in response to the COVID-19 pandemic, which includes assessing and updating these plans on an ongoing basis. The company has developed and implemented return-to-workplace protocols designed to ensure the health and safety of its employees, customers, and business partners. The company is deploying its capabilities, expertise, and scale to address critical health needs related to COVID-19, including the development of diagnostic tests and providing support to firms developing vaccines and therapies. The acquisitions of Cytiva and Aldevron are expected to provide additional sales and earnings opportunities by expanding product line diversity and complementing the company's bioprocessing workflow and genomic medicine solutions. The company’s capital expenditures are primarily aimed at increasing manufacturing capacity, supporting new product development, and improving information technology systems. The company expects to incur higher capital spending in 2022 to support customer demand for products related to testing, treatment, and vaccine production for COVID-19 and other growth opportunities. The company continues to generate substantial cash from operating activities and believes that its operating cash flow, cash on hand, and other sources of liquidity will be sufficient to allow it to continue investing in existing businesses, consummating strategic acquisitions, and managing its capital structure. The company’s businesses are expected to leverage IT capabilities to enhance operational efficiency and support business strategies, which are essential for transforming the firm into a competitive force. The company’s IT resources and capabilities are integral to mobilizing and deploying IT-based resources in combination with other resources and capabilities to further organizational goals. The company’s strategic management practices, including investment decisions and resource allocation, are designed to enhance its operational flexibility and responsiveness to market dynamics. The company’s focus on information management capability underscores the importance of providing data and information to users with appropriate levels of accuracy, timeliness, reliability, and security, tailored to changing business needs and directions.